Information for professionals

Medical updates

1º Jornada sobre el uso del Cannabis en Epilepsia a la Sociedad Medica de Perú



CONVUPIDIOL - Seguimiento de uso de Convupidiol® en pacientes con Epilepsia refractaria (farmacorresistente)

Titular de Autorización de Registro y Comercialización (TARC): Alef Medical Argentina S.A.

Equipo de Farmacovigilancia/IPRAT S.A.

Fecha: 01-Abril-2022

Descargar pdf aquí

Simposio LACE 2021 con la participación de la Dra. Helen Cross

En el marco del Simposio LACE llevado a cabo el 17 de septiembre 2021, la Dra. Helen Cross, Presidente de la Liga Internacional contra la Epilepsia (ILAE), dio una charla donde expuso la siguiente temática: “Uso de cannabinoides en el tratamiento de la epilepsia”. 



Webinar del Instituto Nacional de Ciencias Neurológicas de Lima, Perú, con la participación del Dr. Roberto Caraballo

El Dr. Roberto Caraballo (MN 61.757) Medico Especialista en Neurología Infantil y Epilepsia, Jefe del Servicio de Neurología del Hospital Garrahan y Vicepresidente de la Liga Mundial contra la Epilepsia (ILAE), participa del Panel de Expertos del webinar organizado por el Departamento de Neuropediatra del Instituto Nacional de Ciencias Neurológicas de la ciudad de Lima en Perú, llevado a cabo el 8 de septiembre de 2021. 


Su exposición giró en torno de la siguiente temática: “Uso del Cannabidiol en la Epilepsia: Un Futuro Promisorio o Una Realidad”.



Simposio LACE 2021 con la participación del Dr. Orrin Devinsky

En el marco del Simposio LACE llevado a cabo el 17 de septiembre 2021, el Dr. Orrin Devinsky, Profesor de Neurología, Neurociencias, Psiquiatría y Neurocirugía de la Facultad de Medicina de New York, dio una charla donde expuso la siguiente temática: “Cannabis en el uso de epilepsia y otras indicaciones”.


Trabajo "Estudio randomizado, placebo controlado para tratamiento con cannabidiol como aad-on en la epilepsia resistente por Esclerosis Tuberosa" Autor: Thiele, E.A et al.

Estudio de eficacia de cannabidiol en epilepsia refractaria por esclerosis tuberosa, con dosis de 25mg/k/d y 50 mg/kg/d vs placebo.Add-on Cannabidiol Treatment for Drug-Resistant Seizures

Paper: “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome” By Dr. Orrin Devinsky


In this double-blind, placebo-controlled trial, we randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg or placebo, in addition to standard antiepileptic treatment. 14-week treatment period.

Results: The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo. The percentage of patients who had at least a 50% reduction in convulsive-seizure frequency was 43% with cannabidiol and 27% with placebo

Devinsky et al. N Engl J Med 2017;376:2011-20.

Paper: “A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?” By Dr. Helen Cross


In this paper,  Dr. Helen Cross, warns about the risks of artisanal preparations, not only due to the impossibility to check the amount of CBD per flask and its stability but because of the risk of inconsistency or unknown constituents. Because of the characteristics and the elaboration of these flasks it is impossible to perform clinical studies to compare them with pharmaceutical products with GMP

1. J Helen Cross , Hannah Cock. A Perspective on Cannabinoids for Treating Epilepsy: Do They Really Change the Landscape? Neuropharmacology 2020 Jun 15;170:107861.

Paper: “Cannabis and epilepsy” By Dr. Rhys H. Thomas and Dr. Mark O. Cunningham


Review on the “state of art” of Cannabis and epilepsy, warns about the differences between pharmaceutical cannabis and artisanal preparations. Concludes by suggesting to separate ourselves from our thoughts about artisanal preparations. Cannabidiol oils rigorously tested in clinical trials.

Research Letter: “Labeling Accuracy of Cannabidiol Extracts Sold Online” By Marcel O. Bonn-Miller, PhD; Mallory J. E. Loflin, PhD; Brian F. Thomas, PhD

Work made by researchers of UPenn in JAMA who performed a comparison between contents of commercialized products, founding great discrepancies between what was initially announced and the eventual results. The discrepancies was found both in the CBD and the THC. It outstands the importance of standardizing manufacturing processes.

Paper: “Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol” “ By José A. S. Crippa, Ana C. S. Crippa, Jaime E. C. Hallak, Rocio Martín-Santos, and Antonio W. Zuardi”


Work by Crippa and others, reporting 2 cases of THC intoxication due to artisanal preparations. It highlights the importance of access to GMP products. It also mentions the risks of using of artisanal oils in teens and children because of the known damage produced by Δ9-THC in the developing brain.

News article: “Study finds artisanal CBD not as effective as pharmaceutical CBD for reducing seizures” By Doctor Nathan T. Cohen, M.D., of Children's National Hospital in Washington D.C.


News about the work presented in the American Academy of Neurology 72nd Annual Meeting in Toronto, Canada, April 25 to May 1, 2020. With regards to the difference of impact between home-made products containing CBD and pharmaceutical products. There was higher efficacy noticed in pharmaceutical products rather than in artisanal ones. “The difference in seizure control is dramatic and is definitely of concern since many people continue to use artisanal CBD”, Said lead author Cohen.

Presentation delivered by Dra. Helen Cross “Cannabinoids available and used in clinical practice and their impact on the treatment of epilepsy”

This is the talk delivered by Dr. Helen Cross, President of ILAE (International League Against Epilepsy) on the 15th of October 2020 within the 2020 LACE Congress framework.

Presentation delivered by Dr. Gabriel Martino “Convupidiol launch – LACE Congress 2020”



35 ML - Oral Solution

Each ml. of oral solution contains

  • Cannabidiol 100,00 mg
  • Vanilla flavor
  • Sesame oil
Download prospectus PDF

Professionals Contact

Please complete the required information. We will contact you as soon as possible.